In Zhao2019_PD1-Glioblastoma and Gide2019_PD1+CTLA4-Melanoma cohorts, high-CD44-expression patients exhibited the unfavorable OS relative to low-CD44-expression counterparts, representing a worse immunotherapy outcome. This evidence concerns the gene CTLA4 and melanoma.